Losada Isabel, Cañizares Angeles, Hellín Teresa, Martí-Belda Paloma, Guerrero Antonio
Servicio de Microbiología, Complexo Hospitalario Juan Canalejo, A Coruña, Spain.
Enferm Infecc Microbiol Clin. 2002 Jan;20(1):25-7. doi: 10.1016/s0213-005x(02)72727-4.
The objective of this study was to investigate the prevalence of resistance of herpes simplex virus to acyclovir and foscarnet.
An in vitro susceptibility study of HSV strains isolated from HIV-infected and non-infected (control group) patients was conducted by means of qualitative screening. When the screening results were positive, the method for reducing cytopathic effect was utilized for calculating ID50. An ID50 < 1 microgram/ml indicated susceptibility to acyclovir, ID50 1-2 microgram/ml was intermediate susceptibility to acyclovir and a value of ID50 >/= 2 microgram/ml denoted resistance. Resistance to foscarnet was considered at ID50 >/= 100 microgram/ml.
The study involved investigating 84 HSV strains, 49 HIV-infected patients, and 19 control patients. In the control group, no strains resistant to acyclovir were present and infection recurred in only one patient. In patients with HIV infection, one acyclovir resistant strain was detected and one moderately resistant to acyclovir, with good response to acyclovir treatment. In this group, 24.4% of patients presented recurrent infection. No resistance to foscarnet was detected.
Percentage of HSV strains resistant to acyclovir is very low and resistance to foscarnet was not detected. These data suggest that routine in vitro susceptibility testing of antiviral drugs against HSV does not seem to be necessary.
本研究的目的是调查单纯疱疹病毒对阿昔洛韦和膦甲酸钠的耐药率。
通过定性筛选对从感染HIV和未感染(对照组)患者中分离出的HSV毒株进行体外药敏研究。当筛选结果为阳性时,采用减少细胞病变效应的方法计算半数感染量(ID50)。ID50 < 1微克/毫升表明对阿昔洛韦敏感,ID50为1 - 2微克/毫升为对阿昔洛韦中度敏感,ID50≥2微克/毫升表示耐药。当ID50≥100微克/毫升时认为对膦甲酸钠耐药。
该研究涉及调查84株HSV毒株、49例感染HIV的患者和19例对照患者。在对照组中,不存在对阿昔洛韦耐药的毒株,仅1例患者感染复发。在感染HIV的患者中,检测到1株对阿昔洛韦耐药毒株和1株对阿昔洛韦中度耐药毒株,对阿昔洛韦治疗反应良好。在该组中,24.4%的患者出现感染复发。未检测到对膦甲酸钠耐药的情况。
对阿昔洛韦耐药的HSV毒株比例非常低,未检测到对膦甲酸钠耐药的情况。这些数据表明,针对HSV的抗病毒药物进行常规体外药敏试验似乎没有必要。